Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Phase 1 Unknown 20 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models, TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and hematological malignancies.

Timeline

Start: 2021-08-01
Primary completion: 2022-07-01
Completion: 2022-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQB2928	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.